StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) stock

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07+0.00 (0.00%)

Close on Nov 18, 2026Market cap $773.79MP/E –Yield –

Monte Rosa Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Monte Rosa Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $28.73M, down 83.9% year over year. For fiscal 2025 it was $123.67M, up 63.5% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$123.67M+63.5%
FY2024Dec 31, 2024$75.62M–
FY2023Dec 31, 2023$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$8.97M-61.3%
Q1 FY2026Mar 31, 2026$4.21M-95.0%
Q4 FY2025Dec 31, 2025$2.78M-95.4%
Q3 FY2025Sep 30, 2025$12.77M+38.5%
Q2 FY2025Jun 30, 2025$23.19M+394.0%
Q1 FY2025Mar 31, 2025$84.93M+7882.0%
Q4 FY2024Dec 31, 2024$60.65M–
Q3 FY2024Sep 30, 2024$9.22M–
Q2 FY2024Jun 30, 2024$4.70M–
Q1 FY2024Mar 31, 2024$1.06M–
Q4 FY2023Dec 31, 2023$0–
Q3 FY2023Sep 30, 2023$0–
Q2 FY2023Jun 30, 2023$0–
Q1 FY2023Mar 31, 2023$0–

More Monte Rosa Therapeutics figures

See a number that looks wrong?